Nociception and Pain Receptors
Touch a hot stove and two distinct sensations arrive in sequence. First comes a sharp, well-localized stab. A second, duller, burning ache follows a beat later and lingers. This two-part experience — first pain and second pain — is not a quirk of perception. It is a direct readout of two different populations of sensory nerve fibers. These fibers carry two different molecular alarm systems. They also conduct signals at two different speeds. Nociception is the process by which the nervous system detects and encodes noxious stimuli. These include temperature extremes, intense mechanical force, and tissue-damaging chemicals. It matters because it is the sensory foundation of protective behavior. When it malfunctions, it produces chronic pain. This condition affects roughly a fifth of adults worldwide. It is one of the largest burdens on the healthcare system. Understanding nociception has been transformed over the last three decades. This transformation came through molecular identification of the actual sensor proteins. These are the TRP (transient receptor potential) channel family. They convert heat, cold, acid, and irritant chemicals directly into electrical signals. This conversion happens in free nerve endings. Unlike Somatosensory Mechanoreceptors and Tactile Coding, nociceptors work differently. That system relies on specialized encapsulated end organs (Meissner corpuscles, Pacinian corpuscles). Those organs detect gentle, innocuous stimuli. Nociceptors, by contrast, are largely bare, unencapsulated nerve endings. They respond only when a stimulus crosses into a damaging or potentially damaging range. This article builds on the anatomy of the somatosensory periphery. It also builds on Somatosensory Pathways and Cortical Maps. It explains, at the molecular and cellular level, how nociceptors detect noxious heat, cold, mechanical force, and chemical irritants. It explains why pain has two temporally distinct components. It also describes what classic experiments established this framework. It sets up the transmission and modulation machinery. This includes dorsal horn circuits, ascending pathways, and descending control. These topics are covered under Pain Pathways and Central Modulation.
- Nociceptors are primary sensory neurons (mostly Aδ and C fibers) whose free nerve endings transduce noxious heat, cold, mechanical force, and chemical irritants into action potentials.
- TRP channels (TRPV1, TRPM8, TRPA1) are the principal molecular thermosensors/chemosensors; each has a characteristic temperature and ligand tuning.
- First pain is fast, sharp, and well-localized, carried by thinly myelinated Aδ fibers (~5–30 m/s); second pain is slow, dull, and diffuse, carried by unmyelinated C fibers (~0.5–2 m/s).
- Most nociceptors are polymodal, responding to multiple stimulus types via distinct channels co-expressed in the same ending.
- Peripheral sensitization (e.g., via bradykinin, prostaglandins lowering TRPV1 threshold) explains inflammatory hyperalgesia and is a direct target of NSAIDs and capsaicin-based analgesics.
- Capsaicin's action on TRPV1 (Julius and colleagues, 1997) was the key experiment linking a specific channel to a specific sensory quality, founding the modern molecular era of pain research.
Pain begins when specific TRP-channel-equipped free nerve endings convert noxious heat, cold, force, or chemicals into action potentials carried to the spinal cord by two speed-separated fiber classes, producing the fast/sharp "first pain" and slow/dull "second pain" of ordinary experience.
The core idea
Nociception is the neural process of encoding and processing noxious stimuli — stimuli that threaten or cause tissue damage. It is distinct from pain, which is the conscious, often emotionally colored perceptual experience that (usually, but not always) results from nociceptive input; the two can dissociate, as in congenital insensitivity to pain (nociception without pain) or central neuropathic pain (pain without peripheral nociceptive drive). Nociceptors are the primary afferent sensory neurons — pseudounipolar cells with somata in the dorsal root ganglia (or trigeminal ganglion for the face) — whose peripheral terminals are free, unencapsulated nerve endings ramifying in skin, muscle, joints, and viscera. Unlike low-threshold mechanoreceptors, nociceptors have a high activation threshold: they are silent at innocuous stimulus intensities and fire only as intensity approaches or exceeds the tissue-damage range. Nociceptors are functionally classified along three overlapping axes: the fiber type carrying the signal (thinly myelinated Aδ versus unmyelinated C fibers, distinguished by conduction velocity), the modality to which they respond (thermal, mechanical, chemical, or combinations thereof — most are polymodal), and their molecular transduction machinery (which specific ion channels populate the ending). The key conceptual advance of the last thirty years, driven largely by the cloning of TRP channels, is that a stimulus modality is not an abstract category but a direct chemical/physical property (temperature, protonation, electrophilic reactivity) sensed by a specific, identifiable membrane protein. This replaced older, purely anatomical or "labeled line" theories with a mechanistic molecular vocabulary that lets you predict, for a given channel's biophysical tuning curve, exactly what a neuron will report as painful.
Mechanism
Step 1 — the ending and the fiber. Nociceptor axons branch extensively in the epidermis and dermis (or muscle/viscera) as free nerve endings, lacking the specialized accessory structures of mechanoreceptors. Two fiber classes dominate:
| Fiber type | Diameter | Myelination | Conduction velocity | Typical role |
|---|---|---|---|---|
| Aδ | 1–5 µm | Thin myelin | ~5–30 m/s | Fast, sharp "first pain"; noxious heat/mechanical |
| C | 0.4–1.2 µm | Unmyelinated | ~0.5–2 m/s | Slow, dull, burning "second pain"; polymodal, chemical |
Aδ nociceptors themselves split into two subtypes: Type I (high mechanical threshold, high heat threshold, but sensitizes and responds vigorously to sustained heat >53 °C) and Type II (low heat threshold, very high mechanical threshold), the latter thought to underlie the first, fast pricking heat pain. The great majority of C fibers are polymodal nociceptors (often abbreviated CMH, C mechano-heat) responding to heat, mechanical pressure, and chemical irritants all in the same ending; a subset are heat-insensitive, and a further subset — "silent" or "sleeping" nociceptors, largely found in viscera and joints — are mechanically insensitive at baseline but acquire mechanosensitivity after inflammatory sensitization.
Step 2 — molecular transduction of heat. The founding molecule of the field is TRPV1, cloned by David Julius's group in 1997 as the receptor for capsaicin, the pungent ingredient of chili peppers. TRPV1 is a nonselective cation channel (relatively Ca²⁺-permeable) that opens in response to:
- Noxious heat, threshold ≈ 43 °C
- Capsaicin and related vanilloids
- Extracellular protons (acidosis, pH < 6)
- Some inflammatory lipids
Because capsaicin and heat converge on the same channel, chili peppers feel "hot" — a direct molecular explanation for a previously mysterious cross-modal perceptual fact. TRPV2 responds to even higher noxious heat (threshold ≈ 52 °C), extending the encoded range. On the cold side, TRPM8 is the principal cold and menthol receptor, activated by temperatures below about 25–28 °C and by cooling compounds (menthol, icilin), which is why menthol produces a cooling sensation independent of actual temperature change. Very noxious cold (< ~15 °C) additionally recruits TRPA1, giving cold nociception a biphasic profile — innocuous cooling via TRPM8, painful cold via TRPA1 (and some mechanosensitive/other channels), though the precise noxious-cold threshold channel remains debated.
Step 3 — molecular transduction of chemical and inflammatory signals. TRPA1 ("the wasabi receptor") is a broad electrophile sensor, activated by mustard oil (allyl isothiocyanate), acrolein (found in tear gas and cigarette smoke), and many reactive endogenous inflammatory mediators, making it a general chemical-irritant and inflammatory-pain channel. Acid-sensing ion channels (ASICs), a separate family (degenerin/ENaC superfamily, not TRP channels), detect tissue acidosis directly and contribute to ischemic and inflammatory pain (e.g., the burn of lactic acid buildup during muscle ischemia). ATP released from damaged cells activates P2X (especially P2X3) ionotropic purinergic receptors on nociceptor terminals, signaling tissue injury directly.
Step 4 — mechanotransduction. Noxious mechanical transduction is less completely solved molecularly than thermal transduction, but Piezo2 (a mechanically gated cation channel, Nobel-recognized in Ardem Patapoutian's work) contributes to mechanical pain in addition to its central role in touch, while Piezo1 and other candidate channels contribute in some contexts. High-threshold mechanoreceptors (Aδ and C fiber) require substantially more force to activate than tactile mechanoreceptors, consistent with a higher intrinsic gating tension or a distinct accessory complex.
Step 5 — encoding and peripheral sensitization. Once a TRP or other channel opens, cation influx (Na⁺, Ca²⁺) depolarizes the peripheral terminal; if depolarization reaches threshold, voltage-gated Na⁺ channels (notably the nociceptor-enriched, TTX-resistant Nav1.7, Nav1.8, Nav1.9) generate action potentials that propagate centrally along the axon to the dorsal horn. Crucially, the transduction threshold is not fixed. Tissue injury releases an "inflammatory soup" — bradykinin, prostaglandin E2, histamine, nerve growth factor, protons, ATP — that acts on G-protein-coupled and tyrosine kinase receptors on the nociceptor terminal, triggering PKA/PKC-mediated phosphorylation of TRPV1 and Nav channels. This lowers TRPV1's heat-activation threshold (from ~43 °C toward normal body temperature, ~37 °C) and increases channel open probability — the molecular basis of peripheral sensitization, experienced as primary hyperalgesia (increased pain to a given noxious stimulus) and allodynia (pain to normally innocuous stimuli, e.g., warm water feeling painfully hot on sunburned skin).
Step 6 — from periphery to spinal cord. Aδ nociceptor central terminals synapse mainly in lamina I and V of the spinal dorsal horn; C fiber nociceptors terminate mainly in lamina I and lamina II (substantia gelatinosa), using glutamate as the fast transmitter plus neuropeptides (substance P, CGRP) for slower, modulatory co-transmission. This laminar organization, and the ascending pathways it feeds (spinothalamic tract), is the subject of Pain Pathways and Central Modulation; here it matters only insofar as the two fiber classes maintain their segregation even at this first synaptic relay, preserving the temporal and qualitative first/second pain distinction into central processing.
The evidence
Capsaicin and the cloning of TRPV1 (Caterina, Schumacher, Tominaga, Rosen, Levine & Julius, 1997). For decades, physiologists knew capsaicin selectively excited and eventually desensitized a subset of unmyelinated sensory neurons, and that it produced a burning pain qualitatively similar to heat pain — but the receptor was unknown. Using an expression-cloning strategy, Julius's group screened a cDNA library from dorsal root ganglion neurons in Xenopus oocytes and, later, HEK293 cells, searching for the clone that conferred capsaicin-evoked Ca²⁺ influx. They identified a single cDNA encoding a six-transmembrane-domain, nonselective cation channel — VR1, later renamed TRPV1. Critically, when expressed heterologously, this same channel was also directly activated by heat with a threshold around 43 °C — almost exactly the psychophysical threshold at which humans begin to report burning pain — and by extracellular acidification. This single experiment did three things at once: it identified the first mammalian heat-sensing molecule, it explained mechanistically why capsaicin and heat feel similar (they gate the same channel), and it inaugurated molecular nociception as a field, providing a template (heterologous expression + calcium imaging + electrophysiology) subsequently used to clone TRPM8, TRPA1, and other sensory channels. Confirming causation rather than mere correlation, TRPV1 knockout mice (Caterina et al., 2000; Davis et al., 2000) showed markedly reduced behavioral and electrophysiological responses to noxious heat and capsaicin, though they retained some residual heat sensitivity — evidence that TRPV1 is a major, but not the sole, noxious heat transducer.
Menthol and TRPM8 (McKemy, Neuhausser & Julius, 2002; Peier et al., 2002). Parallel expression-cloning approaches, searching for menthol-sensitive channels in sensory neurons, identified TRPM8, activated both by cooling and by menthol — again directly explaining a cross-modal perceptual phenomenon (menthol "feels cold") via a single shared molecular gate. TRPM8 knockout mice show large deficits in cold avoidance behavior and in cold-fiber electrophysiological responses, confirming TRPM8 as the principal cool/cold transducer for innocuous and mildly noxious cold.
First versus second pain: differential nerve block (going back to Henry Head's self-experiments, early 1900s, and rigorously confirmed with pharmacological/pressure nerve block studies mid-20th century). Selective compression or local anesthetic block of a peripheral nerve can differentially silence large myelinated fibers before unmyelinated fibers (compression block preferentially affects large fibers; low-dose local anesthetic preferentially blocks small fibers first, though the classic double-pain demonstrations use compression block to isolate Aδ vs C conduction). When Aδ fibers are selectively blocked, a pinprick or brief heat pulse to the skin no longer produces the initial sharp pain — only the delayed, dull second pain remains, arriving after the longer C-fiber conduction delay. Conversely, blocking C fibers preferentially (achievable at low local-anesthetic doses that spare large fibers less completely, or inferred from differential fiber diameter–conduction velocity relationships) leaves the first, sharp pain intact but abolishes the delayed burning component. Microneurography — recording directly from single identified C and Aδ afferents in awake human subjects (pioneered by Åke Vallbo, Karl-Erik Hagbarth, and colleagues from the 1960s onward) — directly confirmed that stimulating a single identified C-nociceptor axon (via intraneural microstimulation) evokes a delayed, dull, poorly localized pain sensation matching its slow conduction velocity, while stimulating a single Aδ nociceptor evokes a rapid, sharp, well-localized pinprick sensation. This is among the most direct available demonstrations that fiber type — not just stimulus intensity — determines pain quality.
Peripheral sensitization: bradykinin and PGE2 potentiation of heat responses (multiple groups, 1980s–1990s). Applying inflammatory mediators such as bradykinin or prostaglandin E2 to isolated nociceptor recordings, or injecting them intradermally in human volunteers, lowers the heat-pain threshold and increases firing to a given heat stimulus, without directly activating the fiber at rest — the electrophysiological signature of sensitization rather than direct excitation. Subsequent biochemical work showed PKA/PKC-dependent phosphorylation of TRPV1 mediates much of this threshold shift, directly linking a well-known clinical phenomenon (inflammatory hyperalgesia, e.g., sunburned skin feeling painfully hot in a warm shower) to a defined molecular mechanism.
Worked examples
Example 1 — timing the double pain. A patient's finger is pricked; the sharp first pain and the following dull second pain are both perceived when the stimulus originates 1.0 meter from the spinal cord (roughly the conduction distance from a hand to the cervical spinal cord along the arm and brachial plexus, a simplification for teaching purposes). Take Aδ conduction velocity as 15 m/s and C-fiber conduction velocity as 1 m/s, and assume comparable central transmission delays are negligible for this illustrative estimate. Conduction time, Aδ: t = distance / velocity = 1.0 m / 15 m/s ≈ 0.067 s ≈ 67 ms. Conduction time, C fiber: t = 1.0 m / 1 m/s = 1.0 s = 1000 ms. The interval between first and second pain ≈ 1000 − 67 = 933 ms, roughly one second — consistent with the classic psychophysical observation that second pain lags first pain by about half a second to two seconds for stimuli delivered at the hand or foot, scaling with the length of the limb (a stimulus applied near the shoulder or face produces a much shorter, sometimes barely perceptible, gap because conduction distance is short for both fiber types). This calculation illustrates why proximal noxious stimuli (face, trunk) tend to produce a single, fused pain percept, while distal stimuli (fingers, toes) cleanly separate into two discriminable phases — a direct, quantitative consequence of the conduction-velocity mismatch between fiber classes, not a difference in transduction mechanism.
Example 2 — a clinical reasoning case: congenital insensitivity to pain versus small-fiber neuropathy. A 6-year-old presents with a history of painless fractures, unnoticed burns, and self-inflicted oral mutilation from teething, but entirely normal touch, vibration, proprioception, and cooling sensation on exam. A second, 52-year-old patient with longstanding diabetes presents with burning, tingling pain in both feet, but preserved vibration sense and proprioception, alongside reduced pinprick and thermal sensitivity on quantitative sensory testing. Reasoning through the first case: painless injury with normal mechanoreceptive and cooling function localizes the deficit specifically to nociceptive small-fiber function while sparing large myelinated Aβ fibers (touch/vibration/proprioception, covered under Somatosensory Mechanoreceptors and Tactile Coding) and — interestingly — sparing TRPM8-mediated cooling in this vignette, pointing toward a defect selectively affecting nociceptor development or excitability. This matches the real biology of loss-of-function mutations in SCN9A, the gene encoding Nav1.7, a voltage-gated sodium channel highly enriched in nociceptors and sympathetic neurons; because Nav1.7 amplifies subthreshold depolarization specifically in these small-diameter neurons, its loss prevents nociceptor action potential firing even though TRP-channel transduction and non-nociceptive fiber function remain intact — a clean genetic dissociation between the transduction step (which may still occur) and the encoding step (which fails). (Gain-of-function SCN9A mutations produce the converse clinical picture, erythromelalgia, with severe burning pain from mild warmth or exercise.) The second case runs the opposite direction: gradual, length-dependent loss of small unmyelinated and thinly myelinated fiber function (classic diabetic small-fiber neuropathy, driven by chronic hyperglycemia-related metabolic and microvascular injury to distal nerve terminals) reduces normal protective pain sensation (raising injury risk, e.g., unnoticed foot ulcers) while paradoxically generating spontaneous burning neuropathic pain — because damaged, partially denervated or ectopically firing nociceptor fibers and altered central sensitization can produce pain signaling in the absence of, or disproportionate to, an actual external noxious stimulus. This illustrates the core dissociation introduced earlier: nociception (peripheral detection) and pain (the ultimate perceptual/behavioral output) are not the same process and can be decoupled in either direction — pain without adequate nociceptive input, or nociceptive damage without appropriate protective pain.
Common misconceptions & traps
| Misconception | Correction |
|---|---|
| "Pain receptors" are a single uniform receptor type | Nociceptors are heterogeneous: Aδ vs C fibers, multiple TRP/ASIC/Piezo/Nav channel combinations, polymodal vs modality-specific, silent vs active |
| Capsaicin "burns" the tongue chemically like an acid | Capsaicin causes no tissue damage; it gates TRPV1, the same channel gated by real heat, producing an identical neural signal and thus an identical sensation |
| Pain intensity is a simple linear readout of stimulus intensity | Peripheral and central sensitization can amplify or distort the relationship; hyperalgesia and allodynia reflect gain changes, not stimulus changes |
| Nociception and pain are the same thing | Nociception is peripheral detection/encoding; pain is the resulting (and modifiable) conscious experience — they can dissociate, as in congenital insensitivity to pain or central neuropathic pain |
| "First pain" and "second pain" reflect different stimulus intensities | They reflect different fiber types and conduction velocities from the same stimulus, not different intensities |
| More myelination always means "more important" signal | Thin/absent myelination in nociceptors is a functional tradeoff — small fiber diameter allows enormous numbers of independent nociceptive channels to be packed into a nerve, at the cost of speed |
The scientist behind it
Origins · 1 minDavid Julius and how this was discovered
David Julius is a molecular physiologist whose laboratory transformed pain research from a largely electrophysiological and pharmacological discipline into a molecular one. Trained in biochemistry, he turned to sensory neuroscience in the 1990s, asking a deceptively simple question: what molecule allows capsaicin, and heat, to excite the same population of sensory neurons? His expression-cloning strategy — screening thousands of candidate cDNAs from sensory ganglia for the one that conferred capsaicin sensitivity on a naïve cell — succeeded in 1997 with the identification of TRPV1, the first heat-gated ion channel found in any organism. He subsequently extended the approach to identify TRPM8 (cold/menthol) and, with collaborators, TRPA1 and other sensory channels, and used cryo-electron microscopy to solve TRPV1's atomic structure, revealing how capsaicin, heat, and protons each engage the channel through distinct but allosterically coupled mechanisms. For this body of work he shared the 2021 Nobel Prize in Physiology or Medicine with Ardem Patapoutian, who independently identified the Piezo mechanotransduction channels.
Where this matters today
Molecular nociception research has directly reshaped analgesic drug development. TRPV1 antagonists were pursued as non-opioid analgesics, though early clinical candidates were limited by on-target hyperthermia (since TRPV1 also participates in thermoregulation), spurring more selective or peripherally restricted approaches. Capsaicin itself, exploiting TRPV1-mediated defunctionalization of nociceptor terminals after prolonged activation, is used clinically as a topical patch (high-concentration capsaicin, 8%) for postherpetic neuralgia and diabetic peripheral neuropathic pain. Nav1.7-targeted drugs are being developed based directly on the human genetics of congenital insensitivity to pain (SCN9A loss-of-function) and erythromelalgia/paroxysmal extreme pain disorder (SCN9A gain-of-function), aiming for opioid-sparing analgesics with reduced central and addictive liability since Nav1.7 is comparatively restricted to peripheral nociceptors and sympathetic neurons. NSAIDs (aspirin, ibuprofen) act mechanistically by blocking cyclooxygenase-mediated prostaglandin synthesis, directly preventing the PGE2-driven peripheral sensitization of TRPV1 and Nav channels described above — a century-old drug class whose mechanism was only fully explained by late-20th-century molecular nociception work. Quantitative sensory testing, which measures thermal and mechanical pain thresholds using calibrated stimuli, is now a standard clinical and research tool for diagnosing small-fiber neuropathies (diabetic, chemotherapy-induced, HIV-associated) and for stratifying patients in analgesic clinical trials. In veterinary medicine and livestock husbandry, understanding of nociceptor biology informs pain assessment and analgesia protocols in species that cannot self-report, while in conservation and wildlife biology it shapes debate over which taxa (e.g., invertebrates, fish) possess nociceptive versus fully conscious pain-like processing — an actively contested area with direct animal-welfare policy implications.
Ask the tutor: How does dorsal horn circuitry translate these peripheral first- and second-pain signals into the ascending pathways and descending control systems that shape the final pain experience?
Why does menthol feel cold even though it doesn't change skin temperature?
Menthol directly binds and opens TRPM8, the same ion channel that is gated by actual cooling of the skin below roughly 25–28 °C. Because the nervous system has no independent way to distinguish "TRPM8 opened by cold" from "TRPM8 opened by a chemical ligand," the brain interprets both as the sensation of coolness. This is precisely analogous to why capsaicin feels hot: it opens TRPV1, the same channel gated by noxious heat above about 43 °C. In both cases, a plant-derived chemical hijacks a thermosensory channel, producing a temperature illusion — direct evidence that sensory quality is determined by which channel/neural population is activated, not by the physical nature of the stimulus itself.
What exactly is the difference between nociception, pain, and suffering?
Nociception is the strictly physiological process — transduction and encoding of noxious stimuli by nociceptor sensory neurons and their central relays. Pain is the resulting subjective, conscious perceptual experience, which depends on nociceptive input but is also heavily shaped by attention, expectation, prior experience, and descending modulatory circuits, so it can be amplified, suppressed, or in rare cases generated without corresponding nociceptive input (as in some neuropathic and phantom-limb pain). Suffering is a broader affective/emotional and cognitive construct — the distress associated with pain, illness, or loss — that extends beyond the sensory pain experience itself and is shaped by psychological and social context. All three are related but experimentally and clinically separable.
Are all nociceptors polymodal, responding to heat, mechanical force, and chemicals alike?
No, though polymodality is common, especially among C fibers (the classic C-mechano-heat, or CMH, nociceptor). Nociceptor populations are heterogeneous: some Aδ fibers respond primarily to mechanical stimuli with only weak heat sensitivity (Type I), others respond preferentially to heat with very high mechanical thresholds (Type II), and there exist heat-insensitive but mechanically and chemically sensitive C fibers, as well as "silent" or "sleeping" nociceptors that are essentially unresponsive to any stimulus at baseline but become mechanically and thermally sensitive only after inflammatory sensitization. This diversity means the "nociceptor" category is really a functional umbrella term covering multiple molecularly and physiologically distinct cell populations.
How does the first pain/second pain phenomenon relate to referred pain or diffuse aching pain from internal organs?
Visceral nociception is carried almost entirely by thinly myelinated and unmyelinated fibers with sparse innervation density and extensive convergence onto shared dorsal horn neurons that also receive cutaneous input, which is why visceral pain is typically dull, diffuse, poorly localized, and often "referred" to a distant somatic dermatome sharing the same spinal segment (e.g., cardiac ischemia referred to the left arm). Because there is little to no fast Aδ-mediated "first pain" component from viscera analogous to a skin pinprick, visceral pain lacks the sharp, well-localized initial phase seen in cutaneous nociception and instead resembles an extended, generalized version of cutaneous second pain — consistent with the C-fiber-dominated, convergent circuitry underlying it.
Why do NSAIDs relieve inflammatory pain but not most neuropathic pain?
NSAIDs (e.g., ibuprofen, aspirin) inhibit cyclooxygenase enzymes, blocking synthesis of prostaglandins such as PGE2, which are central drivers of peripheral sensitization — the process by which inflamed tissue lowers nociceptor (especially TRPV1 and Nav channel) activation thresholds. This makes NSAIDs highly effective for inflammatory pain (arthritis, tissue injury, postoperative pain) where prostaglandin-driven sensitization is the dominant mechanism. Neuropathic pain, by contrast, typically arises from direct nerve damage, ectopic firing, altered ion channel expression, or central sensitization in the spinal cord and brain, processes largely independent of prostaglandin synthesis — hence NSAIDs are usually ineffective, and drugs targeting neuronal excitability (anticonvulsants like gabapentin) or descending modulation (certain antidepressants) are preferred instead.
What was the significance of microneurography in proving the first/second pain model?
Microneurography allows researchers to insert a fine tungsten microelectrode into an intact human peripheral nerve and record, or electrically stimulate, single identified sensory axons in awake, reporting subjects. This let investigators directly correlate a single axon's conduction velocity and fiber class with the exact quality, timing, and localization of the sensation the subject verbally reported upon stimulation. Stimulating single C-nociceptor axons produced delayed, dull, poorly localized pain matching predicted slow conduction times; stimulating single Aδ nociceptors produced immediate, sharp, well-localized pain. This was a uniquely direct, single-cell-resolution confirmation — in humans, not inferred from animal proxies — that fiber class, not merely stimulus properties, determines perceived pain quality.
Can nociceptors adapt or become less sensitive over time, the way touch receptors do?
Nociceptors generally show little to no adaptation to sustained noxious stimuli — indeed many sensitize (increase firing) rather than adapt (decrease firing) during ongoing tissue injury or inflammation, which makes ecological sense for a warning system that should not "get used to" ongoing damage. This is a sharp contrast with rapidly adapting tactile mechanoreceptors covered under Somatosensory Mechanoreceptors and Tactile Coding, which are specialized to signal changes in touch rather than sustained pressure. That said, repeated high-dose capsaicin application can cause TRPV1-mediated nociceptor terminal defunctionalization (a distinct, longer-term desensitization process exploited therapeutically in high-concentration capsaicin patches), which should not be confused with ordinary rapid sensory adaptation.